Valuation: Guerbet

Market Cap 102M 117M 94.64M 86.89M 164M 11.17B 167M 1.12B 438M 5.56B 439M 430M 18.64B P/E 2026 *
-4.52x
P/E 2027 * 8.77x
Enterprise Value 477M 549M 444M 408M 770M 52.41B 782M 5.24B 2.06B 26.09B 2.06B 2.02B 87.49B EV / Sales 2026 *
0.62x
EV / Sales 2027 * 0.59x
Free-Float
36.58%
Yield 2026 *
-
Yield 2027 * 2.89%
1 day+3.36%
1 week-5.38%
1 month-15.66%
3 months-34.34%
6 months-44.43%
Current year-47.66%
1 week 7.05
Extreme 7.05
7.77
1 month 7.05
Extreme 7.05
8.72
Current year 7.05
Extreme 7.05
14.92
1 year 7.05
Extreme 7.05
22.75
3 years 7.05
Extreme 7.05
39.4
5 years 7.05
Extreme 7.05
43.65
10 years 7.05
Extreme 7.05
89.68
Manager TitleAgeSince
Chief Executive Officer - 02/02/2026
Chief Executive Officer - 22/09/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 44 29/05/2015
Director/Board Member 50 19/05/2017
Director/Board Member 51 22/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
+3.36%-5.38% - - 117M
-0.84%+5.24%-13.34%-18.64% 14.02B
+4.81%-6.82%+37.66%-8.13% 3.9B
+1.81%+11.70%-36.87%-55.63% 1.27B
-4.57%-3.84%+55.74%+106.83% 1.16B
+1.98%+9.99%-35.09%-44.14% 1.18B
+1.35%+5.63%-43.85% - 952M
+17.03%+10.93%+29.36%+96.15% 500M
-1.79%+1.39%+70.25% - 329M
+0.36%+2.02%-59.87%+221.90% 265M
Average +2.35%+1.42%+0.44%+42.62% 2.62B
Weighted average by Cap. +0.68%+2.16%-3.55%-8.30%

Financials

2026 *2027 *
Net sales 764M 879M 711M 653M 1.23B 83.88B 1.25B 8.38B 3.29B 41.76B 3.3B 3.23B 140B 798M 918M 743M 682M 1.29B 87.66B 1.31B 8.76B 3.44B 43.64B 3.45B 3.37B 146B
Net income -35.8M -41.18M -33.32M -30.59M -57.77M -3.93B -58.67M -393M -154M -1.96B -155M -151M -6.56B 8.3M 9.55M 7.73M 7.09M 13.39M 911M 13.6M 91.06M 35.74M 454M 35.86M 35.07M 1.52B
Net Debt 376M 432M 350M 321M 606M 41.25B 616M 4.12B 1.62B 20.53B 1.62B 1.59B 68.85B 370M 426M 345M 316M 598M 40.67B 607M 4.06B 1.59B 20.24B 1.6B 1.56B 67.88B
Logo Guerbet
Guerbet is a European leader in producing and selling contrast products for medical imaging. The group's products make it possible to visualize different organs and the lymphatic and vascular systems of the human body by making them opaque. Net sales break down by product family as follows: - X-ray imaging products (54.4%); - MRI products (32.1%); - other (13.5%): contrast products for echography and nuclear medicine, fine chemicals products. At the end of 2024 the group had 8 production sites located in France (4), the United States (2), Ireland and Brazil. Net sales are distributed geographically as follows: Europe/Middle East/Africa (43.8%), Americas (29.7%) and Asia (26.5%).
Employees
2,700
Date Price Change
31/07/26 €7.380 +3.36%
30/07/26 €7.140 +1.28%
29/07/26 €7.050 -4.99%
28/07/26 €7.420 -4.50%
27/07/26 €7.770 -0.38%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
8.060EUR
Average target price
8.433EUR
Spread / Average Target
+4.63%

Quarterly revenue - Rate of surprise